SCHEDULE: Rubric Capital Discloses 4.73% Stake in Collegium Pharma
Ownership Disclosure
Rubric Capital Management LP and David Rosen reported a 4.73% beneficial ownership stake in Collegium Pharmaceutical, Inc. as of December 31, 2025.
Summary
- Rubric Capital Management LP and David Rosen collectively reported beneficial ownership of 1,496,436 shares of Collegium Pharmaceutical, Inc. common stock.
- This ownership represents 4.73% of Collegium Pharmaceutical, Inc.'s outstanding common stock.
- The percentage is based on 31,610,976 shares outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Rubric Capital Management LP is an investment adviser, and David Rosen is its Managing Member.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional ownership stake (4.73%) by Rubric Capital Management LP suggests investor confidence in Collegium Pharmaceutical, Inc., even if it's a passive holding.
Positives
- A significant institutional investor, Rubric Capital Management LP, holds a substantial stake, potentially signaling confidence in Collegium Pharmaceutical, Inc.
Future Outlook
NA
Management Comments
- Rubric Capital Management LP and David Rosen certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that the disclosure of a significant stake by an investment adviser like Rubric Capital Management LP can be viewed by the market as a vote of confidence in Collegium Pharmaceutical, Inc.'s long-term prospects, aligning with broader trends of institutional interest in specialized pharmaceutical companies.
Stakeholder Impact
- Shareholders may view the institutional ownership as a positive indicator of the company's value and future potential.
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date of shares outstanding calculation (31,610,976 shares) as reported in the Issuer's Form 10-Q. |
| 2025-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2026-02-13 | Filing date of the Schedule 13G Amendment No. 2. |
Keywords
Collegium Pharmaceutical, Rubric Capital Management, David Rosen, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.